| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Mitchell Shawnte | CHIEF LEGAL OFFICER | C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO | /s/ Shawnte Mitchell | 04 Feb 2026 | 0001749432 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OLMA | Stock Option (Right to Buy) | Award | $0 | +220,000 | $0.000000 | 220,000 | 02 Feb 2026 | Common Stock | 220,000 | $25.65 | Direct | F1 | |
| transaction | OLMA | Performance Stock Options (Right to Buy) | Award | $0 | +56,250 | $0.000000 | 56,250 | 02 Feb 2026 | Common Stock | 56,250 | $25.65 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| F2 | The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. |